Table II.
Bioactive Equivalence Evaluation of Candidate BECCs and MRCs by In Vitro Assays
| In vitro assay | Candidate BECCs (I) | MRCs (I) | Candidate BECCs (II) | MRCs (II) | Candidate BECCs (III) | MRCs (III) |
|---|---|---|---|---|---|---|
| HUVECs | ||||||
| Cell viability | 2.1–13.2% | 1.5–23.6% | 20.7–58.8% | 23.7–44.8% | 77.0–100.4% | 77.8–107.7% |
| LDH | – | – | – | – | 79.6–93.6% | 73.5–91.1% |
| ROS | – | – | – | – | 78.6–85.1% | 73.7–79.0% |
| Macrophages | ||||||
| NO | 10.5–18.0% | 8.4–13.0% | 49.0–56.0% | 53.1–63.1% | 80.6–92.3% | 91.8–100.4% |
| IL-6 | – | – | – | – | 81.7–84.1% | 78.6–81.0% |
| PGE2 | – | – | – | – | 120.1–150.0% | 147.1–185.3% |
| Cardiomyocytes | ||||||
| Cell viability | 38.3–47.8% | 13.7–52.1% | 22.5–27.3% | 8.2–23.0% | 75.6–105.9% | 77.3–104.8% |
n = 3. Bioactive equivalence was evaluated by two one-sided t test. The 90% CI of relative efficacy of candidate BECCs and MRCs compared to original CP was showd in the table. If the 90% CI of relative efficacy fell within the range of 70–143%, the candidate BECCs were considered to be a bioactive equivalent with original Cardiotonic Pill
BECCs bioactive equivalent combinatorial components; MRCs mixture of reference compounds